Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9162408 | 1.00 | PABPC1 (0.38) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL9430245 | 0.84 | PABPC1 (0.36) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL9162801 | 0.82 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL9159223 | 0.82 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL29392716 | 0.80 | PABPC1 (0.36) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL26054727 | 0.80 | PABPC1 (0.36) | PABPC1CTDSP1GAA | |
| SCHEMBL14932765 | 0.76 | PABPC1 (0.36) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL26598823 | 0.76 | ALDH1A1 (0.47) | PABPC1CTDSP1GAASIGMAR1ALDH1A1 | |
| SCHEMBL1030223 | 0.74 | HCRTR2 (0.39) | TMEM97SIGMAR1 | |
| SCHEMBL2038232 | 0.74 | HCRTR2 (0.39) | TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389643-B1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INT LTD (IN) | 2023-05-03 | — | — | EP | claimed |
| US-10576147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2020-03-03 | — | — | US | claimed |
| US-20180360957-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2018-12-20 | — | — | US | claimed |
| EP-3389643-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | Bharat Biotech International Limited (IN) | 2018-10-24 | — | — | EP | claimed |
| WO-2017103944-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2017-06-22 | — | — | WO | claimed |
| EP-3389643-B1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INT LTD (IN) | 2023-05-03 | — | — | EP | disclosed |
| CN-108883080-B | Muramyl peptide derivative compounds, their synthesis and use thereof | 巴拉特生物技术国际有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-10576147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2020-03-03 | — | — | US | disclosed |
| US-20180360957-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2018-12-20 | — | — | US | disclosed |
| EP-3389643-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | Bharat Biotech International Limited (IN) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103944-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2017-06-22 | — | — | WO | disclosed |
| EP-0426253-B1 | Process for the separation of R and S-2,2R1, R2-1,3-dioxolane-4-carboxylic acid | SHELL INT RESEARCH (NL) | 1995-02-22 | — | — | EP | disclosed |
| US-5164519-A | Process for the separation of R and S-2,2-R1,R2 -1,3-dioxolane-4-carboxylic acid | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1992-11-17 | — | — | US | disclosed |
| EP-0426253-A1 | Process for the separation of R and S-2,2R1, R2-1,3-dioxolane-4-carboxylic acid | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-05-08 | — | — | EP | disclosed |
| US-RE31512-E | SISOMICIN BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-31 | — | — | US | disclosed |
| US-4235888-A | SISOMYCIN-TYPE ANTIBIOTICS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360957-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | NOD2, HM13, HLA-DRB1 | PABPC1 3553/4885CTDSP1 1594/4885GAA 4157/4885 |
| US-10576147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | NOD2, HM13, QRFPR | PABPC1 3286/4885CTDSP1 1213/4885GAA 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.